Navigation Links
Lithium chloride slows onset of skeletal muscle disorder
Date:3/18/2008

Irvine, Calif., March 18, 2008 -- A new UC Irvine study finds that lithium chloride, a drug used to treat bipolar disorder, can slow the development of inclusion body myositis, a skeletal muscle disease that affects the elderly.

In the study by scientists Frank LaFerla and Masashi Kitazawa, mice genetically engineered to have IBM demonstrated markedly better motor function six months after receiving daily doses of lithium chloride, compared with non-treated mice. The muscles in treated mice also had lower levels of a protein that the study linked to muscle inflammation associated with IBM.

These data are the first to show that lithium chloride is a potential IBM therapy.

"Lithium chloride is an approved drug for treating humans. We already know it is safe and can be used by people," said LaFerla, professor of neurobiology and behavior at UCI and co-author of the study. "Given our findings, we believe a clinical trial that tests the effectiveness of lithium chloride on IBM patients should be conducted as soon as possible."

Results of the study appear online this month in the journal Annals of Neurology.

IBM is the most common skeletal muscle disorder among people older than 50. People with IBM experience weakness, inflammation and atrophy of muscles in their fingers, wrists, forearms and quadriceps. There is no cure for IBM, nor is there an effective treatment, according to the National Institutes of Health.

LaFerla, a noted Alzheimer's disease researcher, began studying IBM about 10 years ago after learning the disorders have similar tissue characteristics. In the brain, a buildup of phosphorylated tau protein leads to the development of tangles, one of the two lesions that are hallmarks of Alzheimer's disease. High phospho-tau levels also are present in IBM, though patients do not experience dementia or memory loss. In a previous study,

LaFerla found that lithium chloride reduced phospho-tau levels in mice genetically engineered to develop Alzheimer's disease. LaFerla and his research team then wondered: Could lithium chloride also reduce phospho-tau levels and symptoms in mice with IBM?

First, they sought to determine how the inflammation affects the skeletal muscle fibers. They injected the mice with a drug to trigger muscle inflammation, then put them on tiny treadmills to test their motor function. As expected, mice with inflammation could not keep up with the control mice, indicating reduced motor function. Examining their brain tissue, the scientists discovered the mice with muscle inflammation also had higher levels of phospho-tau.

Through additional testing, they discovered an enzyme called GSK-3 beta was responsible for increasing the tau phosphorylation. Previous studies have shown that same enzyme to cause tau buildup in the Alzheimer's brain.

Next, the scientists sought to block the accumulation of phospho-tau in the IBM mice with the goal of curbing motor function loss. In mice six months of age, one group was fed lithium chloride-laced food for six months, and a second group was fed regular food. At 12 months of age, mice in the first group performed on the treadmill as if they were six months of age, while mice in the second group had reduced motor function. Lithium chloride, the scientists found, blocked the GSK-3 beta enzyme that caused higher levels of phospho-tau.

"The older animals were performing as if they were younger animals," said Kitazawa, a postgraduate researcher of neurobiology and behavior at UCI and co-author of the study. "Lithium chloride was delaying their rate of decline."

The scientists then sought evidence that their results in mice might translate to humans with IBM. They performed tests on human muscle tissue samples and found the GSK-3 beta enzyme again played a role in the phosphorylation of tau. That was not the case, though, in patients with other muscle disorders. "This suggests that our IBM mouse model may have the same skeletal muscle mechanism as in human cases," LaFerla said.


'/>"/>

Contact: Jennifer Fitzenberger
jfitzen@uci.edu
949-824-3969
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Possible genetic predictor for response to lithium augmentation in depressed patients
2. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
3. OSHA Extends Comment Period for Lookback Review of Methylene Chloride Standard
4. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
5. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
6. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
7. Amneal Receives FDA Approval for Bethanechol Chloride Tablets, USP Using New Expedited FDA Approval Process
8. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
9. Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics
10. High zinc status in lung cells slows growth and induces DNA damage-induced gene expression
11. Viral Therapy Slows Pediatric Tumors in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... medical device compliance and commercialization, has just released a new white paper ... is more adamant than ever about medical device, pharmaceutical, and combination product ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and industry-leading compliance software, The Guard®, has helped another long-time client pass their ... audit and properly satisfy the law. , Thanks to the help of the ...
(Date:9/20/2017)... ... , ... The Centers for Medicare and Medicaid Services (CMS) stated in the ... only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments over the ... on October 17, 2017 at 2 P.M. EST and uncover how you can ...
(Date:9/20/2017)... ... 2017 , ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: ... ADDICTION” is the creation of published author, Bill Miller. Bill Miller has ... including more than a decade of addiction to prescription drugs. He has ...
(Date:9/20/2017)... ... , ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl yearning to ... Jeanine Liston, a busy mother of five who used her time waiting for children to ... for over twenty years. It was a way to give some meaning to the ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the ... has been granted Fast Track status by the US Food ... HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will ... sequential therapy targeting patients who are admitted to Emergency Departments ... ...
(Date:9/5/2017)... 2017  Just 18 months after its February 2016 ... announce the appointment of three new senior people to ... Dominic Jones-Phillips and James Wright bring ... Tammy Wynne joins as ... writers. She has over ten years, experience in global ...
(Date:8/31/2017)... YORK , Aug. 31, 2017 PM360,s ... industry,s must-read guide to the latest innovations happening across ... first industry publication to focus on providing a comprehensive ... Ultimately, the issue covers the most innovative companies, startups, ... "Everyone in this ...
Breaking Medicine Technology: